Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The many faces of type I interferon in systemic lupus erythematosus
Claudia Mauri, Madhvi Menon
Claudia Mauri, Madhvi Menon
Published June 22, 2015
Citation Information: J Clin Invest. 2015;125(7):2562-2564. https://doi.org/10.1172/JCI82574.
View: Text | PDF
Commentary

The many faces of type I interferon in systemic lupus erythematosus

  • Text
  • PDF
Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a broad spectrum of clinical presentations involving multiple organ systems. An abnormal response to self-antigens is thought to drive the development of SLE; however, the factors that underlie this dysfunction are not clear. In this issue of the JCI, Li and colleagues present compelling evidence to show that type I interferons (IFNs) produced by plasmacytoid dendritic cells inhibit the clearance of apoptotic cells (ACs) by marginal zone macrophages. Specifically, type I IFNs increase the translocation of marginal zone (MZ) B cells to the follicular region of the spleen, thereby disrupting interactions between these B cells and MZ macrophages (MZMs), which in turn disrupts megakaryoblastic leukemia 1–mediated (MKL1-mediated) mechanosensing and inhibits AC phagocytosis by MZMs. The results of this study provide important insight into factors that inhibit AC clearance and promote the development of SLE.

Authors

Claudia Mauri, Madhvi Menon

×

Figure 1

AC clearance in healthy individuals and patients with SLE.

Options: View larger image (or click on image) Download as PowerPoint
AC clearance in healthy individuals and patients with SLE.
(A) mLT-expre...
(A) mLT-expressing MZ B cells interact with LTβR-expressing MZMs in the perifollicular region of the spleen, which promotes MKL1 expression by MZMs and maintains their numbers and phagocytic function. (B) In lupus spleens, pDCs accumulate at the perifollicular region and produce IFNα, which induces the migration of mLT+ MZ B cells to the follicle. This results in the loss of MZM numbers and function, leading to defective AC clearance and loss of tolerance to self-antigens. Furthermore, MZ B cells in the follicle interact with FDCs and T follicular helper (Tfh) cells and stimulate germinal center reactions that result in autoantibody production. The antinuclear autoantibodies form immune complexes to further stimulate pDCs to produce type I IFNs. Amplification of these defective interactions contributes to and perhaps initiates the pathogenesis of SLE.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts